Gatehouse bio
WebDec 4, 2024 · Gatehouse Bio is a bio-data company accelerating the development of next generation therapeutics. Their “sRNAlytics Platform” illuminates molecular pathways of … WebGatehouse Bio uses 1 email formats: 1. first '.' [email protected] (100.0%). Enter a name to find & verify an email >>> Rocketreach finds email, phone & social media for 450M+ professionals. Try for free at rocketreach.co Gatehouse Bio Email Format gatehousebio.com Emails Toggle navigation {{ userNotificationState.getAlertCount('bell') }}
Gatehouse bio
Did you know?
WebMar 13, 2024 · Gatehouse Bio is currently developing its lead targets into biomarker-guided precision therapies for the treatment of pulmonary, cardiac, neurological, and autoimmune diseases. Code-Breaker’s ... WebNov 14, 2024 · www.gatehousebio.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Discovery Tools (Healthcare) …
WebAs founder and CEO of Gatehouse Bio, David has over 14 years of research expertise and experience in microRNA and sRNA biology. He is the force behind the science and technological development required for identifying sRNA diagnostics, targeted assay design, validation, and subsequent product development. WebSep 8, 2024 · Gatehouse Bio is a biotech company developing effective therapeutics using AI that harnesses the power of small RNA. Their platform discovers disease-associated mutations and designs therapeutics...
WebDec 29, 2024 · Technologies. Gatehouse Bio’s ‘sRNAlytics platform’ identifies novel small RNA (sRNA) signatures and illuminates molecular pathways correlated to and potentially … WebSep 30, 2024 · Gatehouse Bio has raised a total of $7.9M in funding over 6 rounds. Their latest funding was raised on Sep 30, 2024 from a Seed round. Gatehouse Bio is funded by 3 investors. SOSV and IndieBio are the most recent investors. Funding Rounds Number of Funding Rounds 6 Total Funding Amount $7.9M
WebSep 8, 2024 · Gatehouse Bio is a biotech company developing effective therapeutics using AI that harnesses the power of small RNA. Their platform discovers disease-associated mutations and designs therapeutics to counteract their effect. For more information visit http://gatehousebio.com/ and follow us on Twitter @gatehousebio
WebGatehouse Bio is a bio-data company in collaboration with AstraZeneca for the identification of new targets for respiratory and cardiovascular diseases using Gatehouse Bio’s AI-powered platform. The sRNAlytics platform identifies small RNA (sRNA) signatures in sequencing data and points to molecular pathways that correlate to or potentially ... thekwane holdings pty ltdWebMar 13, 2024 · Gatehouse Bio, a TechBio company utilizing AI to decode the landscape of small RNAs (sRNAs) and digitally design precision oligonucleotide therapeutics, announced today that its Chief Executive... thekwane villageWebThe Gatehouse Alliance provides consulting, training and development products in the areas of Creativity, Innovation and Organizational Effectiveness. We've provided products, training and consulting to over 100,000 people in the last 10 years. Gatehouse works with a wide range of clients in the private, public and nonprofit sectors. Our ... thekwanes nest self-catering chaletsWebSep 9, 2024 · Gatehouse Bio is engaged in developing small RNA-based therapeutics using AI technology. Using its platform, the company has discovered mutations that are associated with disease and also designs … the kwarantined krab release dateWebWE ARE GATEHOUSE BIO We believe there is an RNA code that drives every disease Our mission is to find that code and use it to develop effective therapeutics Our Code … Technology - Home - Gatehouse Bio Biology - Home - Gatehouse Bio Gatehouse Bio has used its Code-Breaker™ Platform to analyze multiple … News & Publications - Home - Gatehouse Bio Prior to Gatehouse Bio, Matt was a database engineer at Epic Hosting, … Contact us To learn more about our technology or to speak with us about a … the kwan thrillersWebSep 9, 2024 · Under the expanded partnership, AstraZeneca and Gatehouse Bio will jointly develop RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). HFpEF is a heterogenous condition where patients will experience signs and symptoms of HF due to high left ventricular (LV) filling pressure, along with multiple interrelated diseases. the k waveWebGatehouse Bio develops technology capable of classifying patient samples with binary accuracy. The company utilizes a proprietary software suite that identifies small RNA biomarkers. The products address an immediate need to incorporate biomarkers into drug development to satisfy FDA requirements, de-risk programs, and unlock billions of ... the kwangju bank ltd